HIIFS
ZVRA icon

Harel Insurance Investments & Financial Services’s Zevra Therapeutics ZVRA Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$615K – 882
2021
Q1 		$615K Buy
+20,000
New +$175K 0.01% 473

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Harel Insurance Investments & Financial Services's ZVRA Position: Q2 2021 in Review

Harel Insurance Investments & Financial Services sold out of Zevra Therapeutics (ZVRA) in Q2 2021, closing a stake of 20,000 shares — an estimated $615K sold.

Harel Insurance Investments & Financial Services first reported a position in ZVRA in Q1 2021 and held it in 1 quarter. The position peaked at $615K in Q1 2021. 70 funds tracked by Wall St. Rank hold ZVRA as of Q2 2021.

  • Harel Insurance Investments & Financial Services reported no remaining Zevra Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 20,000 Zevra Therapeutics shares in Q2 2021, an estimated $615K.
  • Harel Insurance Investments & Financial Services first reported a position in Zevra Therapeutics in Q1 2021 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Zevra Therapeutics position peaked at $615K in Q1 2021.
  • 70 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2021.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2021, filed 26 Jul 2021.